Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial
Journal
Lung cancer (Amsterdam, Netherlands)
Journal Volume
169
Date Issued
2022-07
Author(s)
Soo, Ross A
Huat Tan, Eng
Hayashi, Hidetoshi
Seto, Takashi
Ou, Sai-Hong Ignatius
Kim, Dong-Wan
Liu, Geoffrey
Abbattista, Antonello
Martini, Jean-François
Hooi Wong, Chew
Toffalorio, Francesca
Solomon, Benjamin J
Abstract
To analyze the efficacy and safety of lorlatinib in Asian and non-Asian patients with pretreated anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (NSCLC) from a phase 1/2 study.
Subjects
Anaplastic lymphoma kinase; Asian; Lorlatinib; Non-small cell lung cancer; Tyrosine kinase inhibitor
Type
journal article